Moderna (NASDAQ: MRNA)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-03 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 4.590 | 5.240 | 0.6500 | ||||
REV | 4.070B | 4.749B | 679.000M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Moderna (NASDAQ: MRNA) through any online brokerage.
Other companies in Moderna’s space includes: Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Ionis Pharmaceuticals (NASDAQ:IONS).
The latest price target for Moderna (NASDAQ: MRNA) was reported by Morgan Stanley on Thursday, August 4, 2022. The analyst firm set a price target for 197.00 expecting MRNA to rise to within 12 months (a possible 5.44% upside). 27 analyst firms have reported ratings in the last year.
The stock price for Moderna (NASDAQ: MRNA) is $186.84 last updated August 5, 2022, 8:00 PM UTC.
There are no upcoming dividends for Moderna.
Moderna’s Q3 earnings are confirmed for Thursday, November 3, 2022.
There is no upcoming split for Moderna.
Moderna is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.